These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10603491)

  • 1. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
    MacLean MR
    Trends Pharmacol Sci; 1999 Dec; 20(12):490-5. PubMed ID: 10603491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
    McCann UD; Seiden LS; Rubin LJ; Ricaurte GA
    JAMA; 1997 Aug; 278(8):666-72. PubMed ID: 9272900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced pulmonary hypertension: must history repeat itself?
    Voelkel NF
    Pulm Pharmacol; 1996 Apr; 9(2):67-8. PubMed ID: 8880947
    [No Abstract]   [Full Text] [Related]  

  • 4. Selections from current literature: pharmacological treatment of obesity.
    Connolly J; Verni C; Trilling J; Kelso E; Shiesha S
    Fam Pract; 1998 Feb; 15(1):88-93. PubMed ID: 9527304
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenfluramine: riddle or Rosetta stone?
    Weir EK; Obreztchikova M; Hong Z
    Eur Respir J; 2008 Feb; 31(2):232-5. PubMed ID: 18238944
    [No Abstract]   [Full Text] [Related]  

  • 6. [Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].
    Wolf I; Mouallem M; Farfel Z
    Harefuah; 1998 Dec; 135(11):515-7. PubMed ID: 10911468
    [No Abstract]   [Full Text] [Related]  

  • 7. Fenfluramine potentiates canine pulmonary vasoreactivity to endothelin-1.
    Barman SA; Isales CM
    Pulm Pharmacol Ther; 1998; 11(2-3):183-7. PubMed ID: 9918753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis.
    Eddahibi S; Adnot S
    Respir Res; 2002; 3(1):9. PubMed ID: 11806844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anorectics and pulmonary hypertension].
    Bíbová J; Hampl V
    Cas Lek Cesk; 2000 Feb; 139(3):67-70. PubMed ID: 10838744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anorectic drugs and pulmonary hypertension from the bedside to the bench.
    Michelakis ED; Weir EK
    Am J Med Sci; 2001 Apr; 321(4):292-9. PubMed ID: 11307870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension.
    Archer SL; Djaballah K; Humbert M; Weir KE; Fartoukh M; Dall'ava-Santucci J; Mercier JC; Simonneau G; Dinh-Xuan AT
    Am J Respir Crit Care Med; 1998 Oct; 158(4):1061-7. PubMed ID: 9769261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Anchors M
    Arch Intern Med; 1997 Jun; 157(11):1270. PubMed ID: 9183245
    [No Abstract]   [Full Text] [Related]  

  • 13. Fen-phen manufacturers, not physicians, are liable.
    Allen S; Henderson J
    Tex Med; 2000 May; 96(5):62-4. PubMed ID: 10843016
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
    Goldstein SE; Levy Y; Shoenfeld Y
    Harefuah; 1998 Dec; 135(11):489-92, 568. PubMed ID: 10911459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Too late, again?
    Jones NL
    Can Respir J; 2001; 8(3):127-8. PubMed ID: 11420587
    [No Abstract]   [Full Text] [Related]  

  • 16. Synergistic interactions between fenfluramine and phentermine.
    Wellman PJ; Maher TJ
    Int J Obes Relat Metab Disord; 1999 Jul; 23(7):723-32. PubMed ID: 10454106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects.
    Rothman RB; Baumann MH
    Pharmacol Biochem Behav; 2002 Apr; 71(4):825-36. PubMed ID: 11888573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary hypertension as a result of drug therapy.
    Higenbottam T; Laude L; Emery C; Essener M
    Clin Chest Med; 2004 Mar; 25(1):123-31. PubMed ID: 15062604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension.
    Blanpain C; Le Poul E; Parma J; Knoop C; Detheux M; Parmentier M; Vassart G; Abramowicz MJ
    Cardiovasc Res; 2003 Dec; 60(3):518-28. PubMed ID: 14659797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use.
    Rothman RB
    Chest; 2000 Nov; 118(5):1516-7. PubMed ID: 11083718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.